Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced its participation in the SVB Leerink Global Healthcare Conference from February 14-18, 2022. A fireside chat featuring company management is scheduled for February 16, 2022, at 1:00 p.m. Eastern Time. Investors can access the live webcast through a provided link and find the archived presentation on the company’s website. Crinetics focuses on developing novel therapeutics for rare endocrine diseases, with its lead candidate, paltusotine, currently in a Phase 3 clinical program for acromegaly.

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company management will participate in a fireside chat at the annual SVB Leerink Global Healthcare Conference, which is being held in a virtual format February 14-18, 2022.

Details of the presentation are as follows:

Date:	Wednesday, February 16, 2022
Time:	1:00 p.m. Eastern Time
Webcast Link:	https://wsw.com/webcast/svbleerink67/crnx/2679350

In addition, the live and archived presentation will be accessible on the Events & Presentations page in the Investors section on the Company’s website.

About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine, is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 clinical program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of congenital adrenal hyperplasia, Cushing’s disease and other diseases of excess ACTH. All of the company’s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.

Contacts:
Marc Wilson
Chief Financial Officer
IR@crinetics.com
(858) 450-6464

Investors / Media:
Corey Davis
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577

Aline Sherwood
Scienta Communications
asherwood@scientapr.com
(312) 238-8957

FAQ

What is Crinetics Pharmaceuticals' upcoming event related to the stock symbol CRNX?

Crinetics Pharmaceuticals will participate in the SVB Leerink Global Healthcare Conference from February 14-18, 2022, with a fireside chat scheduled for February 16, 2022, at 1:00 p.m. Eastern Time.

How can investors access Crinetics Pharmaceuticals' presentation at the SVB Leerink Conference?

Investors can access the live webcast of Crinetics Pharmaceuticals' presentation at the SVB Leerink Conference through the provided webcast link.

What is the focus of Crinetics Pharmaceuticals according to their recent press release?

Crinetics Pharmaceuticals focuses on discovering, developing, and commercializing novel therapeutics for rare endocrine diseases and endocrine-related tumors.

What is the lead product candidate of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' lead product candidate is paltusotine, which is being developed for the treatment of acromegaly.

What clinical program is underway for Crinetics Pharmaceuticals' lead candidate paltusotine?

A Phase 3 clinical program for paltusotine in the treatment of acromegaly is currently underway.